Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy | ||
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.conicet.organizacion | Medical University of Graz. Department of Medicine | |
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.conicet.organizacion | Kangwon National University School of Medicine | |
| dc.conicet.organizacion | Aarhus University Hospital. Department of Cardiology | |
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.conicet.organizacion | GlaxoSmithKline Heart Failure Discovery Performance Unit | |
| dc.conicet.organizacion | GlaxoSmithKline Heart Failure Discovery Performance Unit | |
| dc.conicet.organizacion | GlaxoSmithKline Heart Failure Discovery Performance Unit | |
| dc.conicet.organizacion | GlaxoSmithKline Heart Failure Discovery Performance Unit | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas | |
| dc.conicet.organizacion | ational Institute of Environmental Health Sciences | |
| dc.conicet.organizacion | GlaxoSmithKline Heart Failure Discovery Performance Unit | |
| dc.conicet.organizacion | Johns Hopkins Medical Institutions. Department of Medicine | |
| dc.contributor.author | Seo, Kinya | |
| dc.contributor.author | Rainer, Peter P. | |
| dc.contributor.author | Shalkey Hahn, Virginia | |
| dc.contributor.author | Lee, Dong-ik | |
| dc.contributor.author | Jo, Su-Hyun | |
| dc.contributor.author | Andersen, Asger | |
| dc.contributor.author | Liu, Ting | |
| dc.contributor.author | Xu, Xiaoping | |
| dc.contributor.author | Willette, Robert N. | |
| dc.contributor.author | Lepore, John J. | |
| dc.contributor.author | Marino, Joseph P. | |
| dc.contributor.author | Birnbaumer, Lutz | |
| dc.contributor.author | Schnackenberg, Christine G. | |
| dc.contributor.author | Kass, David A. | |
| dc.date.issued | 2014-01-28 | |
| dc.description.abstract | Chronic neurohormonal and mechanical stresses are central fea-tures of heart disease. Increasing evidence supports a role forthe transient receptor potential canonical channels TRPC3 andTRPC6 in this pathophysiology. Channel expression for both is nor-mally very low but is increased by cardiac disease, and geneticgain- or loss-of-function studies support contributions to hypertro-phy and dysfunction. Selective small-molecule inhibitors remainscarce, and none target both channels, which may be useful giventhe high homology among them and evidence of redundant sig-naling. Here we tested selective TRPC3/6 antagonists (GSK2332255Band GSK2833503A; IC50,3–21 nM against TRPC3 and TRPC6) andfound dose-dependent blockade of cell hypertrophy signaling trig-gered by angiotensin II or endothelin-1 in HEK293T cells as well as inneonatal and adult cardiac myocytes. In vivo efficacy in mice andrats was greatly limited by rapid metabolism and high protein bind-ing, although antifibrotic effects with pressure overload were ob-served. Intriguingly, although gene deletion of TRPC3 or TRPC6alone did not protect against hypertrophy or dysfunction frompressure overload, combined deletion was protective, support-ing the value of dual inhibition. Further development of thispharmaceutical class may yield a useful therapeutic agent forheart disease management. | es |
| dc.description.fil | Fil: Seo, Kinya. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Rainer, Peter P.. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos. Medical University of Graz. Department of Medicine; Austria | |
| dc.description.fil | Fil: Shalkey Hahn, Virginia. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Lee, Dong-ik. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Jo, Su-Hyun. Kangwon National University School of Medicine; Corea del Sur. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Andersen, Asger. Aarhus University Hospital. Department of Cardiology; Dinamarca | |
| dc.description.fil | Fil: Liu, Ting. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos | |
| dc.description.fil | Fil: Xu, Xiaoping. GlaxoSmithKline Heart Failure Discovery Performance Unit; Estados Unidos | |
| dc.description.fil | Fil: Willette, Robert N.. GlaxoSmithKline Heart Failure Discovery Performance Unit; Estados Unidos | |
| dc.description.fil | Fil: Lepore, John J.. GlaxoSmithKline Heart Failure Discovery Performance Unit; Estados Unidos | |
| dc.description.fil | Fil: Marino, Joseph P.. GlaxoSmithKline Heart Failure Discovery Performance Unit; Estados Unidos | |
| dc.description.fil | Fil: Birnbaumer, Lutz. ational Institute of Environmental Health Sciences; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina | |
| dc.description.fil | Fil: Schnackenberg, Christine G.. GlaxoSmithKline Heart Failure Discovery Performance Unit; Estados Unidos | |
| dc.description.fil | Fil: Kass, David A.. Johns Hopkins Medical Institutions. Department of Medicine; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Seo, Kinya; Rainer, Peter P.; Shalkey Hahn, Virginia; Lee, Dong-ik; Jo, Su-Hyun; et al.; Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy; National Academy of Sciences; Proceedings of the National Academy of Sciences of The United States of America; 111; 4; 28-1-2014; 1551-1556 | es |
| dc.identifier.eissn | 1091-6490 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 0027-8424 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/98932 | |
| dc.journal.ciudad | Washington | es |
| dc.journal.number | 4 | es |
| dc.journal.pagination | 1551-1556 | es |
| dc.journal.pais | Estados Unidos | es |
| dc.journal.title | Proceedings of the National Academy of Sciences of The United States of America | es |
| dc.journal.volume | 111 | es |
| dc.language.iso | eng | es |
| dc.publisher | National Academy of Sciences | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/http://www.pnas.org/content/111/4/1551 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/doi.org/10.1073/pnas.1308963111 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | ION CHANNELS | es |
| dc.subject | CALCIUM | es |
| dc.subject | NUCLEAR FACTOR OF ACTIVATED | es |
| dc.subject | T CELLS | es |
| dc.subject.classification | Bioquímica y Biología Molecular | es |
| dc.subject.classification | Ciencias Biológicas | es |
| dc.subject.classification | CIENCIAS NATURALES Y EXACTAS | es |
| dc.title | Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.2032b1c4-503f-4cfd-9068-7e471290e6cc_A.pdf
- Tamaño:
- 1.3 MB
- Formato:
- Adobe Portable Document Format